Circumventing manufacturing issues due to Covid-19
Situation / Issue
A UK manufacturer offered re-supply for our client’s vaccine trial (2,005 packs), with a 3-month lead time. Our client placed a PO, but upon BAP’s order placement, the manufacturer advised that due to the impact of Covid-19 on their manufacturing capacity, the lead time would be extended to 4 months. Shortly after, the manufacturer updated to advise that they could no longer commit to supply at all during 2020 due to Covid-19.
Faced with a potential interruption of the clinical trial, BAP Pharma mobilised to find an alternative source of the vaccine in question.